Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

• DOI: 10.2147/ijn.s132064
• Publication Date: 2017-07-09T23:52:00Z
• Authors: Quan Qi; Lei Lu; Haiqing Li; Zhize Yuan; Gaoxian Chen; Miao Lin; Zhengwen Ruan; Xiaofeng Ye; Zeyu Xiao; Qiang Zhao
• Keywords: Male; Medicine (General); 0303 health sciences; Myocardial Infarction; Apoptosis; Heart; Liraglutide; Polyethylene Glycols; 3. Good health; Rats, Sprague-Dawley; 03 medical and health sciences; R5-920; Drug Delivery Systems; International Journal of Nanomedicine; Cardiac Regeneration; Animals; Nanoparticles; Regeneration; Myocytes, Cardiac; Spatiotemporal Delivery; Polyglactin 910; Nanoformulated Liraglutide; Original Research

The local, intramyocardial injection of proteins into the infarcted heart is an attractive option to initiate cardiac regeneration after myocardial infarction (MI). Liraglutide, which was developed as a treatment for type 2 diabetes, has been implicated one most promising protein candidates in regeneration. A significant challenge therapeutic use this its short half-life vivo. In study, we evaluated effects and long-term retention liraglutide loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) nanoparticles (NP-liraglutide) on experimental MI. PLGA-PEG (NPs) have shown efficiently load release bioactive sustained manner. For vitro test, released retained bioactivity, measured by ability activate signaling pathways. Next, compared saline, empty NPs, free NP-liraglutide rat model NPs were detected myocardium up 4 weeks. More importantly, sufficient improve function (P<0.05), attenuate infarct size preserve wall thickness promote angiogenesis (P<0.05) prevent cardiomyocyte apoptosis at weeks without affecting glucose levels. controlled, delivery represents effective strategy